EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Third Quarter 2025 Financial Results -- Commercially Launched ORLYNVAHTM in the United States in August 2025— • Launch of ORLYNVAHTM for uUTIs in August 2025: Iterum commercially launched ORLYNVAH™ in the United States. with its commercialization partner, EVERSANA Life Science Services, LLC (EVERSANA), in August 2025. • Expansion of Patent Estate: Iterum has been granted a patent in China as patent number ZL202180020106.6, entitled "Combinations ...